Japan - Business Enterprise Expenditure on R&D Performed in the Pharmaceutical Industry

Since 2014, Japan Business Enterprise Expenditure on R&D Performed in the Pharmaceutical Industry decreased by 0.9% year on year. With $13,899,037,124.73 Million PPP in 2019, the country was ranked number 3 among other countries in Business Enterprise Expenditure on R&D Performed in the Pharmaceutical Industry. Japan is overtaken by China, which was ranked number 2 with $13,956,388,273.35 Million PPP and is followed by Germany with $6,508,976,256.92 Million PPP. United States lead the ranking with $70,565,318,932.39 Million PPP in 2019, a growth of 3.3% compared to 2018. Iceland recorded the best 5 years average growth at +43.9% per year, while Lithuania recorded the worst performance at -42.6% per year.

Loading...

Date Million US Dollars PPP
2019 13,899,037,124.73
2018 13,427,620,084.44
2017 13,905,033,477.54
2016 12,810,755,508.32
2015 14,091,132,754.20
Download all data from 1987 to 2019

How does Japan rank in Business Enterprise Expenditure on R&D Performed in the Pharmaceutical Industry?

# 69 Countries Million US Dollars PPP Last YoY 5‑years CAGR
1 #1
United States
70,565,318,932.39 2019 +3.3 % +4.5 % View data
2 #2
China
13,956,388,273.35 2019 +4.5 % +6.1 % View data
3 #3
Japan
13,899,037,124.73 2019 +3.5 % -0.9 % View data
4 #4
Germany
6,508,976,256.92 2019 +2.7 % +4.4 % View data
5 #5
Switzerland
5,040,677,150.71 2019 +3.2 % +3.8 % View data
Compare all 69 countries

Go Top